- Comprehend new information in pediatric hematology/oncology, including the latest in basic and clinical research.
- Apply knowledge gained in all areas of pediatric hematology/oncology investigation and practice.
- Assemble a network of professional colleagues with whom you can solve problems, share experiences, and provide mutual professional support.
- Challenges of Pediatric Thrombosis: Summarize the natural history of asymptomatic VTEs, describe the current evidence regarding the use of DOACs to treat VTEs in pediatric patients, and discuss strategies to prevent catheter-related VTEs in pediatric patients. Summarize the epidemiology, presentations and pathophysiology of neonatal and pediatric cerebral sinus thrombosis (CSVT), describe the evidence for anticoagulation and potential role of endovascular therapy in managing CSVT, and recognize the critical role of an interdisciplinary team in the detection and management of early and late sequelae of CSVT. Identify transplant-associated thrombotic microangiopathy and its treatment implications, including the impact on the renal system and describe the clinical features and new treatments available for hereditary and acquired TTP. Describe the specific testing to be performed for different settings of thrombophilia, including a positive family history, presence of a new deep vein thrombosis, neonatal stroke, and the initiation of OCPs.
- Cellular Therapy, Gene Editing and Complications of Sickle Cell Disease: Summarize the role of Hematopoietic Stem Cell Transplantation (HSCT), including use of alternative donors, for the treatment of Sickle Cell Disease. Describe recent developments in the use of gene editing to treat Sickle Cell Disease. Develop strategies that promote patient, family and community engagement in the implementation of these potentially curative therapies. Recognize, prevent and manage Sickle Cell Disease- associated neurologic complications.
- Challenges in Pediatric Transfusion Medicine and the Consequences of Iron Overload: Describe indications for transfusion of blood products in neonates, apply practical strategies to decrease exposure to transfusions, and utilize tools for the management of adverse transfusion-associated reactions. Summarize iron metabolism and its regulation as well as the role of non-transferrin bound iron in potential complications in intensively-treated pediatric oncology and HSCT patients. Recognize the potential long-term consequences of iron overload and describe the different laboratory and imaging modalities used for surveillance of iron overload.
- Toxicities (Including Financial Toxicity) associated with Childhood Cancer Treatment: Summarize currently known cardiovascular toxicities associated with anti-cancer treatment modalities, namely conventional chemotherapeutics, biologically targeted agents, immune modulators, and radiation. Recognize the important of a multidisciplinary approach to the prevention, detection, and treatment of these cardiovascular complications. Identify skin toxicities associated with immunotherapy and describe its management. Describe the common treatment-related toxicities associated with radiation and proton beam therapy and emerging agents that may help to alleviate these toxicities. Discuss the role of nutrition and body weight on treatment outcomes for pediatric patients with cancer. Develop and implement risk prediction models for pediatric cancer patients presenting with non-neutropenic versus neutropenic fever. Discuss the utility of DNA molecular techniques for the early detection of infections in immunocompromised pediatric patients. Recognize the prevalence and adverse effects of financial toxicity on long-term outcomes for childhood cancer survivors. Describe the physical and psychosocial challenges that can exacerbate financial toxicity and develop strategies for prevention, intervention and management of financial toxicity for childhood cancer patients.
- Approach to the Patients with Rhabdomyosarcoma and Refractory/Relapsed Sarcoma: Develop evidence-based algorithms for the treatment of recurrent sarcomas. Discuss the potential value of tumor genomic profiling and integration of this information into treatment planning in pediatric patients with refractory/relapsed sarcoma and discuss palliative treatment options for this patient population. Formulate evidence-based treatment regimens for pediatric patients with rhabdomyosarcoma (RMS) and identify novel agents being used for the treatment of refractory/relapsed RMS. Recognize that patients with RMS may have a cancer predisposition cancer syndrome and would benefit from genetic counseling.
- Artificial Intelligence, Machine Learning, and Surveillance to Detect Relapse in Pediatric Patients with Solid Tumors: Summarize the fundamental concepts of artificial intelligence and machine learning and identify opportunities to apply AI tools in pediatric hematology/oncology. Discuss the evidence supporting surveillance imaging in pediatric patients with solid tumors and summarize the risks and costs associated with different imaging modalities used in surveillance.
- Pediatric Lymphoma and Post-Transplant Lymphoproliferative Disorder (PTLD): Describe new discoveries related to the biology of pediatric lymphomas and potential implications for therapy. Summarize new and targeted agents available for the treatment of pediatric Hodgkin Lymphoma. Discuss the use of EBV-targeted cellular therapy in pediatric lymphomas. Utilize the Evidence-Based Practice Guidelines generated from the International Pediatric Transplant Association EBV/PTLD consensus conference for the prevention, diagnosis, evaluation and management of PTLD.
- Pediatric Acute Leukemias and Leukemia Predisposition Syndromes: Describe potential treatment options, including novel agents, and develop treatment algorithms for refractory/relapsed T-ALL. Discuss the indications for CAR-T cell therapy versus HSCT for the treatment of B-ALL and recognize that these two treatment modalities are not mutually exclusive. Identify pediatric patients who may have a genetic predisposition to developing leukemia and recognize the challenges associated with testing and counseling these patients and their families. Develop clinical management strategies for pediatric patients with leukemia predisposition syndromes.
- Genomics of Pediatric Solid Tumors, including CNS Tumors, and Risk-Adapted Therapy for Medulloblastoma: Describe the evolving techniques, identify the most appropriate testing, and interpret the data from genomic analyses of pediatric solid tumor specimens. Distinguish different risk subgroups of pediatric high-grade gliomas based on genomic and epigenomic features. Define risk groups of medulloblastoma based on molecular, epidemiologic, and clinical outcomes data and formulate treatment strategies that decrease treatment-related neurocognitive deficits in infants and young children with medulloblastoma while improving outcomes.
- Emicizumab in Pediatric Patients with Hemophilia A: Summarize the mechanisms of action of Emicizumab and discuss the recent findings from the HAVEN clinical trials. Compare and contrast the use of Emicizumab in previously untreated Hemophilia A patients, those with newly diagnosed inhibitors and those with tolerized inhibitors. Describe the laboratory monitoring of patients receiving Emicizumab and the treatment options for breakthrough bleeds and achieving peri-operative hemostasis.
- Treatment of Neurofibromatosis Type 1 (NF1)- Related Tumors: Summarize the current understanding of the natural history of NF1 optic gliomas and recognize when to intervene with treatment. Discuss the use of targeted agents to treat NF1-associated tumors, namely BRAF/MEK inhibitors for optic pathway gliomas, MEK inhibitors for plexiform neurofibromas, and inhibitors for malignant peripheral nerve sheath tumors.
- Vascular Anomalies Primer: Identify the different types of simple and complex vascular anomalies and describe the methods used to diagnose these different types of vascular anomalies. Discuss the appropriate use of different treatment modalities (e.g., medications, invasive procedures) for simple and complex vascular anomalies.
- Immunology and Immunotherapy: Summarize the salient points of adaptive immunity that underlie the function and toxicities of immunotherapy. Describe the potential toxicities associated with adaptive cell therapy and immune modulators.
- Updates and Opportunities from the FDA for the Pediatric Hematology/Oncology Specialist: Describe FDA regulations and role in the development of safe and effective therapies for pediatric hematologic- and oncologic- related diseases. Recognize the role of expanded access to investigational treatment and execute the procedures for obtaining this expanded access.
- Practical Wellness to Battle Burnout: Acquire techniques in meditation and mindfulness including yoga skills that can be incorporated into daily professional and personal life. Develop strategies to build a wellness program at the home institution that is accessible to providers and staff.
- Improving Clinic Flow in a Hematology/Oncology Outpatient Practice: Discuss tools available to measure and improve clinic flow. Recognize how Real-Time Location Systems (RTLSs) can be implemented in the pediatric hematology/oncology outpatient clinic setting.
Continuing Medical Education Credit
The American Society of Pediatric Hematology/Oncology’s Conference will offer continuing medical education (CME) credit. Credit will be awarded for sessions attended and evaluated. A certificate will be issued upon receipt of the evaluation.
The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 37 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, ASPHO requires all planners, faculty (presenters and moderators), reviewers, teachers, authors, and any others involved in the development of CME content to disclose all financial relationships they have with ineligible companies in the last 24 months. Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product or investigational use of a product not yet approved for this purpose. The ASPHO Accreditation Subcommittee reviews all financial relationships as submitted in the disclosure form by planners and presenters and resolves such conflicts to ensure the content of the activity is aligned with the interests of the public.
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.
Maintenance of Certification (MOC)
ASPHO offers a Maintenance of Certification (MOC) opportunity in the form of an Online MOC Post-Test. The online MOC Post-Test includes faculty written case-based, multiple-choice questions based on the educational sessions. Attendees will receive 10 MOC Part 2 points upon completion of the test questions and a 70% minimum score. When purchased, attendees will be able to access the questions online as part of the evaluation. Participants can have unlimited access to the multiple-choice questions until July 23, 2021. The fee is $50, and advance registration is required.
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 10 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.